SignaCor

Executive Summary

SignaCor is a UK-based precision oncology company pioneering integrated theranostic solutions that combine novel imaging biomarkers with targeted therapies. Founded in 2020 and headquartered in Cambridge, the company addresses significant unmet needs in hard-to-treat cancers by identifying and treating patients most likely to respond. Its lead programs are in Phase 2 clinical development, focusing on tumor types where current diagnostic and therapeutic options are limited. SignaCor's approach has the potential to improve patient outcomes and reduce healthcare costs by enabling more precise treatment selection and monitoring. The company is privately held and has garnered attention for its innovative strategy in the rapidly growing theranostics market, which is expected to exceed $10 billion by 2030.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead theranostic program60% success
• Q4 2026Strategic partnership with a major pharmaceutical company for companion diagnostics50% success
• Q2 2026Orphan Drug Designation or other regulatory milestone for a key program70% success